Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Prognostic Value of Specific Biomarker in Prostate Cancer Authenticated

By LabMedica International staff writers
Posted on 20 Aug 2019
Prostate cancer (PC) is the most commonly diagnosed cancer in Canadian men. In men with high-risk PC, progression of the disease will lead to biochemical recurrence (BCR), distant metastases, and disease-specific mortality.

The extensively studied nuclear factor kappa B (NF-κB) pathway is involved in the regulation of inflammation and the immune response, and more recently demonstrated its importance in cancer development. The activation of the NF-κB signaling pathways can result in the progression of several types of cancer, including PC.

A large team of scientists at the Centre hospitalier de l’Université de Montréal (Montreal, QC, Canada) and their associates accessed two different multi-center tissue microarrays (TMAs) representing cohorts of patients (Test-TMA and Validation-TMA series) of the Canadian Prostate Cancer Biomarker Network (CPCBN) to validate the association between p65 nuclear frequency and PC outcomes. Immunohistochemical staining of p65 was performed on the Test-TMA and Validation-TMA series, which include PC tissues from patients treated by first-line radical prostatectomy (n = 250 and n = 1,262, respectively).

For each patient, 0.6-mm cores (3–4 of tumor tissue and 1–2 of benign adjacent tissue) were punctured from formalin-fixed paraffin-embedded blocks and transferred to receiver blocks. Four-micrometer-thick sections of each TMA block were subjected to antigen retrieval in Cell Conditioning 1 for 90 minutes and then stained using the BenchMark XT autostainer. All sections were scanned using a VS-110 microscope with a 20× 0.75 NA objective and a resolution of 0.3225 μm. Two independent observers evaluated the p65 nuclear frequency in digital images of cancer tissue and benign adjacent gland tissue.

Multivariate analysis of the Validation-TMA cohort showed that p65 nuclear frequency in cancer cells was an independent predictor of BCR using continuous (hazard ratio [HR] 1.02) and dichotomized data (HR 1.33). The team used a cutoff of 3%, and found that this biomarker was also associated with the development of bone metastases (HR 1.82) and PC-specific mortality (HR 2.63), independent of clinical parameters. BCR-free survival, bone-metastasis-free survival, and PC-specific survival were shorter for patients with higher p65 nuclear frequency.

The authors concluded that they had demonstrated the prognostic significance of nuclear p65 in two independent PC TMA cohorts that included primary tumor tissues of patients from multiple institutions. The implementation of this biomarker in the clinical workflow would allow genitourinary pathologists and clinicians to improve the identification of patients with high-risk PC. The study was published on July 2, 2019, in the journal PLOS Medicine.

Related Links:
Centre hospitalier de l’Université de Montréal


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Auto Clinical Chemistry Analyzer
cobas c 703
New
cTnI/CK-MB/Myo Test
Finecare cTnI/CK-MB/Myo Rapid Quantitative Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.